Camp
Spécifications
60-92-4Numéro CAS
200-492-9Numéro CE
(4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-olNom IUPAC
C10H12N5O6PFormule chimique
329.21 g/molMasse molaire
Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine 3',5'-phosphate; Cyclic Adenosine Monophosphate; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine, cyclic 3',5'-(hydrogen phosphate); cyclic Adenosine 3',5'-phosphate; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; Adenosine 3',5'-cyclic phosphate; Adenosine cyclic 3',5'-phosphate; Adenosine cyclic phosphate; Cyclic adenylic acid; DTXSID8040436; E0399OZS9N; (4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol; CHEBI:17489; DTXCID6020436; NSC-143670; Adenosine cyclic 3',5'-(hydrogen phosphate); adenosine cyclic-3',5'-monophosphate; 3',5'-Monophosphate, Adenosine Cyclic; NSC-94017; AMP, Cyclic; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-1,3,5,2$l^{5}-furo[3,2-d][1,3,2$l^{5}]dioxaphosphinin-2-one; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-2lambda5-furo[3,2-d][1,3,2]dioxaphosphinin-2-one; Cyclic Monophosphate, Adenosine; Monophosphate, Adenosine Cyclic; (1S,6R,8R,9R)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3$l^(5)-phosphabicyclo(4.3.0)nonan-9-ol; (1S,6R,8R,9R)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3$l^{5}-phosphabicyclo[4.3.0]nonan-9-ol; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-1,3,5,2$l^(5)-furo(3,2-d)(1,3,2$l^(5))dioxaphosphinin-2-one; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-2lambda5-furo(3,2-d)(1,3,2)dioxaphosphinin-2-one; (4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo(3,2-d)(1,3,2)dioxaphosphinin-7-ol; Adenosine Cyclic 3,5 Monophosphate; Adenosine Cyclic 3',5' Monophosphate; Cyclic 3',5'-Monophosphate, Adenosine; Cyclic-3',5'-Monophosphate, Adenosine; RefChem:26388; 3'5'-cyclic ester of AMP; Adenosine Cyclic 3':5'-Monophosphate; 200-492-9; NSC94017; Adenosine cyclophosphate; Adenosine-3',5'-cyclophosphate; cyclic Adenosine 3',5'-monophosphate; CCRIS 4291; [3H]cAMP; [3H]-cAMP; MFCD00005845; NSC 94017; Adenosine 3',5'-phosphate monohydrate; BRN 0052645; adenosine-3',5'-cyclic monophosphate; adenosine-3',5'-cyclic-monophosphate; CHEMBL316966; Adenosine-3',5'-cyclicmonophosphate; (4aR,6R,7R,7aS)-6-(6-Amino-9H-purin-9-yl)-2,7-dihydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine 2-oxide; C10H12N5O6P; cyclic-AMP; NCGC00093588-03; Adenosine 3,5'-cyclic monophosphoric acid; adenosine-cyclic-phosphate; 3',5'-cAMP; adenosine cyclic-monophosphate; adenosine-cyclic-phosphoric-acid; EINECS 200-492-9; UNII-E0399OZS9N; Adenosine-3',5'-cyclic phosphate; CAS-60-92-4; Cyclo-AMP; 114697-05-1; 3'5'-cyclic AMP; Cyclic AMP (Standard); Regadenoson Impurity 73; CYCLIC AMP; CAMP; CYCLIC AMP [MI]; Cyclic 3',5'-adenylate; bmse000071; Epitope ID:137352; orb64030; SCHEMBL1244; Lopac0_000084; CYCLIC AMP [WHO-DD]; 4-26-00-03618 (Beilstein Handbook Reference); 3' 5'-adenosine monophosphate; GTPL2352; GTPL5096; orb1297731; orb1734047; cAMP; 3',5'-Cyclic AMP; SCHEMBL29352184; BDBM10851; HY-B1511R; MSK6937; TCO2745; cid_23902375; ADENOSINUM CYCLOPHOSPHORICUM; HMS3260A10; HY-B1511; Tox21_113510; Tox21_500084; BDBM50384264; Adenosine 3O,5O-cyclic monophosphate; Adenosine 3',5'-cyclophosphoric acid; Adenosine 3':5'-cyclic monophosphate; Adenosine 3,5'-cyclic monophosphorate; AKOS015999561; Tox21_113510_1; 3', 5'-cyclic adenosine monophosphate; adenosine 3',5'-(hydrogen phosphate); CCG-204179; DB02527; EBC-459110; LP00084; NA08991; SDCCGSBI-0050072.P002; Adenosine 3a(2),5a(2)-cyclophosphate; Adenosine-3',5'-cyclophosphate (cAMP); D-Adenosine 3',5'-cyclic monophosphate; NCGC00093588-01; NCGC00093588-02; NCGC00093588-04; NCGC00093588-06; NCGC00260769-01; AS-13112; SY066620; ADENOSINUM CYCLOPHOSPHORICUM [HPUS]; Adenosine, 3',5'-cyclic-monophosphoric acid; CS-0013299; EU-0100084; NS00122387; ADENOSINE-3 ,5 -CYCLIC-MONOPHOSPHATE; A 9501; A51099; C00575; ADENOSINE CYCLIC-3',5'-(HYDROPHOSPHATE); F213436; Q210041; SR-01000075695; CYCLIC-3',5'-(HYDROGEN PHOSPHATE)ADENOSINE; SR-01000075695-1; 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin, adenosine deriv.; B5C9F048-77DD-4170-A624-23C09E7B080D; Adenosine 3',5'-cyclic monophosphate, >=98.5% (HPLC), powder; ADENOSINE-3':5'-CYCLIC MONOPHOSPHORIC ACID (3:5-CYCLIC AMP); Adenosine 3 inverted exclamation mark ,5 inverted exclamation mark -Cyclic Monophosphate; CAMP;Adenosine 3 inverted exclamation marka,5 inverted exclamation marka-cyclic monophosphat; (1s,6r,8r,9r)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3lambda(5)-phosphabicyclo[4.3.0]nonan-9-ol(1s,6r,8r,9r)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3lambda(5)-phosphabicyclo[4.3.0]nonan-9-ol; (2R,4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-1,3,5,2$l^{5}-furo[3,2-d][1,3,2]dioxaphosphinin-2-one; (4aR,6R,7R,7aS)-6-(6-Amino-9H-purin-9-yl)-2,7-dihydroxytetrahydro-2H,4H-2lambda~5~-furo[3,2-d][1,3,2]dioxaphosphinin-2-one; (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide; (4aR,6R,7R,7aS)-6-(6-Aminopurin-9-yl)-2-oxo-tetrahydro-2-lambda*5*-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol; 4H-furo[3,2-d]-1,3,2-dioxaphosphorin-7-ol, 6-(6-amino-9H-purin-9-yl)tetrahydro-2-hydroxy-, 2-oxide, (4aR,6R,7R,7aS)-; 6-(6-Amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide #Synonymes